ANTERIOR CRUCIATE LIGAMENT AND POSTERIOR CRUCIATE LIGAMENT RECONSTRUCTION DEVICES MARKET ANALYSIS

The anterior cruciate ligament (ACL) and posterior cruciate ligament (PCL) reconstruction is an operation to replace torn ligament to restore the stability of the knee joint. The ACL and PCL are tough bands of tissues in the middle portion of the knee that joins the tibia and the femur and prevents the two imperative bones from sliding or pivoting in an uncontrolled fashion.

Anterior cruciate ligament (ACL) and posterior cruciate ligament (PCL) injuries are classified according to the amount of injury to the functional ligament:

• Grade 1: a partial ACL/PCL tear
• Grade 2: near complete ACL/PCL tear
• Grade 3: a complete ACL/PCL tear, the ligament becomes completely non-functional

The anterior cruciate ligament can be injured in a number of ways. These ligament tears mostly occur due to sudden pivoting or cutting manoeuvre during sporting activity, which is mostly seen in basketball, football. Ligament can also tear due to work injuries or road accidents.

Anterior cruciate ligament (ACL) and posterior cruciate ligament (PCL) reconstruction devices market is estimated to be valued at US$ 10,952 million in 2022 and is expected to exhibit a CAGR of 7.2 % over the forecast period (2022-2030)

Figure 1. Global ACL and PCL Reconstruction Devices Market Value (US$ Mn), By Region, 2022

To learn more about this report, Request sample copy

Increasing ACL and PCL surgeries every year worldwide is expected to drive growth of the global ACL and PCL reconstruction devices market over the forecast period.

For instance, according to data published by National Centre for Biotechnology Information in February 2022, in U.S. annual incidence of ACL Injuries are around 1 in 3,500 people.

Figure 2. Global ACL and PCL Reconstruction Devices Market Share (%), By Procedure Type, 2022

To learn more about this report, Request sample copy

Increasing product launches and approvals are expected to drive the market growth over the forecast period.

For instance, in January 2022, Zynex, Inc., a medical devices manufacturer that manufactures and markets electrotherapy devices for the use in pain management has added post-operative knee braces, which are typically used after orthopaedic surgery such as tendon or meniscus repairs, ACL/PCL/MCL, or fixing fractured knee.

Moreover, in December 2021, Miach Orthopaedics, Inc., a privately held company dedicated to developing bio-engineered surgical implants for connective tissue restoration, has made BEAR implant commercially available in select U.S. cities for the treatment of anterior cruciate ligament (ACL) tears.

Global ACL/PCL Reconstruction Devices Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 a pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 518 million cases of coronavirus disease (COVID-19) were reported till  May 15, 2022, across the globe.

At the inception of covid-19, company’s revenue was impacted and it decreased due to worldwide lockdown. However, in first quarter of 2021 companies endured positivity in revenues due to signs of pandemic began to reduce across many regions by acceleration of vaccine rollout.

For instance, the net sales of Zimmer Biomet Holding, Inc. in the second quarter of 2020 witnessed a decrease of 38.3% from the prior year period.

Moreover, in the second quarter of 2021 Zimmer Biomet Holding, Inc. experienced increase in net sales 65.3% over the prior year period.

Key Players

Major players operating in the global ACL/PCL reconstruction devices market include Miach Orthopaedics, Arthrex, Smith & Nephew, Zimmer Biomet, Conmed Linvatec, MTF, RTI Biologics, Stryker, LifeNet Health, JRF, Parcus Medical, Medtronic, Tissue Regenix, Synthasome, Artelon, MedShape, Rotation Medical, CITIEFFE S.R.L, DJO Global Inc., Johnson & Johnson Services, Inc., and Meira Corporation.